A New Jersey laboratory which had parts of its business acquired by Labcorp earlier this month has laid off 81 employees. BioReference Health terminated the employees from its headquarters in Elmwood ...

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key ...

In April 2024, Entera announced that the Journal of Bone and Mineral Research (JBMR) published EB613 placebo controlled Phase 2 Trial results, highlighting its dual mechanism of action and rapid ...

OPKO Health, Inc. OPK is well-poised for growth in the coming quarters, courtesy of its potential in RAYALDEE. The optimism ...

Investors who take an interest in OPKO Health, Inc. (NASDAQ:OPK) should definitely note that the Chairman & CEO, Phillip Frost, recently paid US$1.74 per share to buy US$348k worth of the stock.

OPKO Health (NASDAQ: OPK) has recently received a number of price target changes and ratings updates: 3/19/2025 – OPKO Health ...

OPKO Health and Entera Bio, a developer of oral peptides and protein replacement therapies, entered into a license agreement ...

Opko Health and Entera Bio have announced a partnership and licence agreement to progress the development of the first oral ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

Stock analysts at HC Wainwright raised their Q2 2025 EPS estimates for shares of OPKO Health in a research report issued to clients and investors on Wednesday, March 12th. HC Wainwright analyst Y.

US biotech OPKO Health (Nasdaq: OPK) and Israeli firm Entera Bio (Nasdaq: ENTX) have entered into a collaboration to develop an oral GLP-1/glucagon dual agonist tablet for obesity, metabolic ...

Opko Health Inc. and Entera Bio Ltd. have entered into a collaboration and license agreement to advance an oral dual agonist GLP-1/glucagon peptide as a once-daily tablet into the clinic for patients ...